CJ-2360
CJ-2360 is a potent and orally active ALK inhibitor with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated.
For research use only. We do not sell to patients.
- CAS No.: 2226742-61-4
- Formula: C27H30FN5O2
- Molecular Weight:475.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KARPAS-299 | IC50 |
1.8 nM
Compound: CJ-2360
|
Antiproliferative activity against human KARPAS-299 cells incubated for 4 days by WST8 or Cell-titer-Glo assay
Antiproliferative activity against human KARPAS-299 cells incubated for 4 days by WST8 or Cell-titer-Glo assay
|
[PMID: 33185101] |
| NCI-H3122 | IC50 |
3 nM
Compound: CJ-2360
|
Antiproliferative activity against human NCI-H3122 cells incubated for 4 days by WST8 or Cell-titer-Glo assay
Antiproliferative activity against human NCI-H3122 cells incubated for 4 days by WST8 or Cell-titer-Glo assay
|
[PMID: 33185101] |
CJ-2360 achieves an IC50 value of 1.8 nM in inhibition of cell growth in the KARPAS-299 cell line. Further tested CJ-2360 for its potency in cell growth inhibition in the H3122 non-small-cell lung cell line carrying EML4-ALK and obtained an IC50 value of 3 nM. CJ-2360 inhibits Mer tyrosine-protein kinase (MERTK), CLK1, DAPK1, DAPK2, and DAPK3 with IC50s of 6.3, 11, 31, 23, 22, and 260 nM, respectively. CJ-2360 displays >100-fold selectivity for ALK over the insulin receptor kinase (INSR) and shows no significant activity against IGF1R[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CJ-2360 (100 mg/kg; p.o.) is very effective in inhibition of ALK phosphorylation, as well as ERK and STAT3 phosphorylation in KARPAS-299 tumor tissue, with the effect persisting for at least 24 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KARPAS-299 xenograft model (female SCID mice)[1]
-
Dosage:100 mg/kg
-
Administration:P.o.; twice daily for 22 days
-
Result:Very efficacious in the KARPAS-299 xenograft model. It achieves complete tumor regression in 100% of tumors and all tumors did not return until day 53, 23 days after the last dose.
Chemical Information
-
CAS No. 2226742-61-4
-
Molecular Weight 475.56
-
Formula C27H30FN5O2
-
SMILES
N#CC1=CC(N2)=C(C3=C2N(C(C)C)C4=C(C=C(OC)C(N5C[C@H](C)N(C)[C@H](C)C5)=C4F)C3=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)